JPS6230752B2 - - Google Patents
Info
- Publication number
- JPS6230752B2 JPS6230752B2 JP59167324A JP16732484A JPS6230752B2 JP S6230752 B2 JPS6230752 B2 JP S6230752B2 JP 59167324 A JP59167324 A JP 59167324A JP 16732484 A JP16732484 A JP 16732484A JP S6230752 B2 JPS6230752 B2 JP S6230752B2
- Authority
- JP
- Japan
- Prior art keywords
- sulfate
- influenza virus
- item
- crosslinked
- cellulose
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Expired
Links
- 241000712461 unidentified influenza virus Species 0.000 claims abstract description 55
- 238000000034 method Methods 0.000 claims abstract description 42
- 229920002678 cellulose Polymers 0.000 claims abstract description 32
- 239000001913 cellulose Substances 0.000 claims abstract description 31
- 229920001282 polysaccharide Polymers 0.000 claims abstract description 20
- 239000005017 polysaccharide Substances 0.000 claims abstract description 20
- -1 sulfuric acid ester Chemical class 0.000 claims abstract description 20
- 238000000746 purification Methods 0.000 claims abstract description 16
- 238000004587 chromatography analysis Methods 0.000 claims abstract description 8
- 238000004440 column chromatography Methods 0.000 claims abstract description 7
- 239000000427 antigen Substances 0.000 claims description 23
- 102000036639 antigens Human genes 0.000 claims description 23
- 108091007433 antigens Proteins 0.000 claims description 23
- QAOWNCQODCNURD-UHFFFAOYSA-L Sulfate Chemical compound [O-]S([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 claims description 19
- 239000012530 fluid Substances 0.000 claims description 13
- 241000700605 Viruses Species 0.000 claims description 12
- 229920000936 Agarose Polymers 0.000 claims description 7
- 241000287828 Gallus gallus Species 0.000 claims description 5
- 229960000633 dextran sulfate Drugs 0.000 claims description 5
- BRLQWZUYTZBJKN-UHFFFAOYSA-N Epichlorohydrin Chemical group ClCC1CO1 BRLQWZUYTZBJKN-UHFFFAOYSA-N 0.000 claims description 4
- 235000013601 eggs Nutrition 0.000 claims description 3
- 241000271566 Aves Species 0.000 claims description 2
- 241001465754 Metazoa Species 0.000 claims description 2
- 239000012930 cell culture fluid Substances 0.000 claims description 2
- 241000282412 Homo Species 0.000 claims 1
- 206010022000 influenza Diseases 0.000 abstract description 11
- 229960005486 vaccine Drugs 0.000 abstract description 9
- 150000004676 glycans Chemical class 0.000 abstract description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N sulfuric acid Substances OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 abstract description 5
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 39
- 235000010980 cellulose Nutrition 0.000 description 24
- 239000000499 gel Substances 0.000 description 21
- 239000008363 phosphate buffer Substances 0.000 description 21
- 239000011780 sodium chloride Substances 0.000 description 20
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 15
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 15
- 239000000203 mixture Substances 0.000 description 11
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 10
- 102000004169 proteins and genes Human genes 0.000 description 9
- 108090000623 proteins and genes Proteins 0.000 description 9
- TZCXTZWJZNENPQ-UHFFFAOYSA-L barium sulfate Chemical compound [Ba+2].[O-]S([O-])(=O)=O TZCXTZWJZNENPQ-UHFFFAOYSA-L 0.000 description 8
- KEQGZUUPPQEDPF-UHFFFAOYSA-N 1,3-dichloro-5,5-dimethylimidazolidine-2,4-dione Chemical compound CC1(C)N(Cl)C(=O)N(Cl)C1=O KEQGZUUPPQEDPF-UHFFFAOYSA-N 0.000 description 7
- XTHPWXDJESJLNJ-UHFFFAOYSA-N chlorosulfonic acid Substances OS(Cl)(=O)=O XTHPWXDJESJLNJ-UHFFFAOYSA-N 0.000 description 7
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 7
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 239000007788 liquid Substances 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- AXISYYRBXTVTFY-UHFFFAOYSA-N Isopropyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OC(C)C AXISYYRBXTVTFY-UHFFFAOYSA-N 0.000 description 5
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 5
- 238000011067 equilibration Methods 0.000 description 5
- 229960003971 influenza vaccine Drugs 0.000 description 5
- 239000002953 phosphate buffered saline Substances 0.000 description 5
- 235000013330 chicken meat Nutrition 0.000 description 4
- 230000000694 effects Effects 0.000 description 4
- XZEUAXYWNKYKPL-URLMMPGGSA-N ormeloxifene Chemical compound C1([C@@H]2[C@H](C3=CC=C(C=C3OC2(C)C)OC)C=2C=CC(OCCN3CCCC3)=CC=2)=CC=CC=C1 XZEUAXYWNKYKPL-URLMMPGGSA-N 0.000 description 4
- 238000001179 sorption measurement Methods 0.000 description 4
- 229920002307 Dextran Polymers 0.000 description 3
- 239000000872 buffer Substances 0.000 description 3
- 239000007853 buffer solution Substances 0.000 description 3
- 230000034994 death Effects 0.000 description 3
- 231100000517 death Toxicity 0.000 description 3
- 238000010828 elution Methods 0.000 description 3
- 230000032050 esterification Effects 0.000 description 3
- 238000005886 esterification reaction Methods 0.000 description 3
- 208000015181 infectious disease Diseases 0.000 description 3
- 150000002632 lipids Chemical class 0.000 description 3
- 238000004519 manufacturing process Methods 0.000 description 3
- 229910052757 nitrogen Inorganic materials 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 125000001174 sulfone group Chemical group 0.000 description 3
- 108010067390 Viral Proteins Proteins 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 229960002086 dextran Drugs 0.000 description 2
- 230000036039 immunity Effects 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- 239000003960 organic solvent Substances 0.000 description 2
- 239000008055 phosphate buffer solution Substances 0.000 description 2
- 238000006116 polymerization reaction Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 238000011084 recovery Methods 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- AKEJUJNQAAGONA-UHFFFAOYSA-N sulfur trioxide Inorganic materials O=S(=O)=O AKEJUJNQAAGONA-UHFFFAOYSA-N 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- DEWLEGDTCGBNGU-UHFFFAOYSA-N 1,3-dichloropropan-2-ol Chemical compound ClCC(O)CCl DEWLEGDTCGBNGU-UHFFFAOYSA-N 0.000 description 1
- FSBYOEHUNSUUTD-UHFFFAOYSA-N 2-(2,5-dioxabicyclo[2.1.0]pentan-3-yloxy)ethanol Chemical compound C1(C2C(O2)O1)OCCO FSBYOEHUNSUUTD-UHFFFAOYSA-N 0.000 description 1
- 241000272517 Anseriformes Species 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000283073 Equus caballus Species 0.000 description 1
- 102000003886 Glycoproteins Human genes 0.000 description 1
- 108090000288 Glycoproteins Proteins 0.000 description 1
- 101710154606 Hemagglutinin Proteins 0.000 description 1
- 241000712431 Influenza A virus Species 0.000 description 1
- 241000713196 Influenza B virus Species 0.000 description 1
- 102000005348 Neuraminidase Human genes 0.000 description 1
- 108010006232 Neuraminidase Proteins 0.000 description 1
- 101710093908 Outer capsid protein VP4 Proteins 0.000 description 1
- 101710135467 Outer capsid protein sigma-1 Proteins 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241000286209 Phasianidae Species 0.000 description 1
- 101710194807 Protective antigen Proteins 0.000 description 1
- 101710176177 Protein A56 Proteins 0.000 description 1
- 229920002684 Sepharose Polymers 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 241000282887 Suidae Species 0.000 description 1
- 238000005377 adsorption chromatography Methods 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- 230000004520 agglutination Effects 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 239000000470 constituent Substances 0.000 description 1
- 238000011109 contamination Methods 0.000 description 1
- 238000004132 cross linking Methods 0.000 description 1
- 239000003431 cross linking reagent Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000010586 diagram Methods 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 230000035931 haemagglutination Effects 0.000 description 1
- 239000000185 hemagglutinin Substances 0.000 description 1
- 238000000703 high-speed centrifugation Methods 0.000 description 1
- 239000012535 impurity Substances 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- 238000009776 industrial production Methods 0.000 description 1
- 238000004255 ion exchange chromatography Methods 0.000 description 1
- 238000000464 low-speed centrifugation Methods 0.000 description 1
- 239000011159 matrix material Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- 239000000376 reactant Substances 0.000 description 1
- 230000006798 recombination Effects 0.000 description 1
- 238000005215 recombination Methods 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 239000012798 spherical particle Substances 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
- 239000006228 supernatant Substances 0.000 description 1
- YNJBWRMUSHSURL-UHFFFAOYSA-N trichloroacetic acid Chemical compound OC(=O)C(Cl)(Cl)Cl YNJBWRMUSHSURL-UHFFFAOYSA-N 0.000 description 1
- 238000000108 ultra-filtration Methods 0.000 description 1
- 238000005199 ultracentrifugation Methods 0.000 description 1
- 238000002255 vaccination Methods 0.000 description 1
- 230000003612 virological effect Effects 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/145—Orthomyxoviridae, e.g. influenza virus
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16134—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
- C12N2760/00011—Details
- C12N2760/16011—Orthomyxoviridae
- C12N2760/16111—Influenzavirus A, i.e. influenza A virus
- C12N2760/16151—Methods of production or purification of viral material
Landscapes
- Life Sciences & Earth Sciences (AREA)
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Virology (AREA)
- General Health & Medical Sciences (AREA)
- Immunology (AREA)
- Medicinal Chemistry (AREA)
- Microbiology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Animal Behavior & Ethology (AREA)
- Mycology (AREA)
- Public Health (AREA)
- Organic Chemistry (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Genetics & Genomics (AREA)
- Wood Science & Technology (AREA)
- Pulmonology (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Detergent Compositions (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Priority Applications (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59167324A JPS6147186A (ja) | 1984-08-09 | 1984-08-09 | インフルエンザウイルスの精製方法 |
| EP85110012A EP0171086B1 (en) | 1984-08-09 | 1985-08-08 | A method for purification of influenza virus |
| AT85110012T ATE54468T1 (de) | 1984-08-09 | 1985-08-08 | Verfahren zur reinigung des influenzavirus. |
| CA000488281A CA1251399A (en) | 1984-08-09 | 1985-08-08 | Method for purification of influenza virus |
| DE8585110012T DE3578613D1 (de) | 1984-08-09 | 1985-08-08 | Verfahren zur reinigung des influenzavirus. |
| KR1019850005760A KR920009733B1 (ko) | 1984-08-09 | 1985-08-09 | 인플루엔자 바이러스의 정제방법 |
| US06/764,128 US4724210A (en) | 1984-08-09 | 1985-08-09 | Method for purification of influenza virus |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP59167324A JPS6147186A (ja) | 1984-08-09 | 1984-08-09 | インフルエンザウイルスの精製方法 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JPS6147186A JPS6147186A (ja) | 1986-03-07 |
| JPS6230752B2 true JPS6230752B2 (en, 2012) | 1987-07-03 |
Family
ID=15847633
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP59167324A Granted JPS6147186A (ja) | 1984-08-09 | 1984-08-09 | インフルエンザウイルスの精製方法 |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US4724210A (en, 2012) |
| EP (1) | EP0171086B1 (en, 2012) |
| JP (1) | JPS6147186A (en, 2012) |
| KR (1) | KR920009733B1 (en, 2012) |
| AT (1) | ATE54468T1 (en, 2012) |
| CA (1) | CA1251399A (en, 2012) |
| DE (1) | DE3578613D1 (en, 2012) |
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2005042737A1 (ja) | 2003-11-04 | 2005-05-12 | Dnavec Research Inc. | 遺伝子導入された樹状細胞の製造方法 |
| EP1662003A2 (en) | 2000-11-08 | 2006-05-31 | DNAVEC Research, Inc. | Paramyxovirus vector for gene transfer to the cardiovascular system |
| WO2006134917A1 (ja) | 2005-06-14 | 2006-12-21 | Dnavec Corporation | 抗体の作製方法 |
| WO2007083644A1 (ja) | 2006-01-17 | 2007-07-26 | Dnavec Corporation | 新規タンパク質発現系 |
| WO2008007581A1 (fr) | 2006-07-13 | 2008-01-17 | Dnavec Corporation | Vecteur de virus paramyxoviridae non répliquant |
| WO2008136438A1 (ja) | 2007-04-27 | 2008-11-13 | Kyushu University, National University Corporation | 遺伝子治療用ウイルスベクター |
Families Citing this family (28)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5158761A (en) * | 1989-04-05 | 1992-10-27 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
| US5215739A (en) * | 1989-04-05 | 1993-06-01 | Toko Yakuhin Kogyo Kabushiki Kaisha | Spray gel base and spray gel preparation using thereof |
| FR2667622B1 (fr) * | 1990-10-08 | 1994-10-07 | Kaysersberg Sa | Montisse lie hydrauliquement et son procede de fabrication. |
| IT1248075B (it) * | 1991-06-18 | 1995-01-05 | Sclavo Spa | Processo per la purificazione del virus dell'epatite a (hav), virus cosi` purificato e composizioni vaccinali che lo contengono. |
| US5447859A (en) * | 1993-07-16 | 1995-09-05 | Viagene | Method for the purification or removal of retroviruses using sulfated cellulose |
| EP1010981A1 (de) * | 1998-12-18 | 2000-06-21 | Diagor GmbH | Konjugate zum Nachweis von Viren und deren Verwendung |
| PL354822A1 (en) * | 2002-06-30 | 2004-01-12 | Instytut Immunologii i Terapii Doświadczalnej PANwe Wrocławiu | Method of receiving purified bacteriophage preparations and new applications of polysaccharide or its esterificated derivative |
| EP1633321A4 (en) * | 2003-06-18 | 2006-11-02 | Onyx Pharma Inc | METHOD FOR CLEANING VIRUS |
| CA2503774C (en) * | 2003-06-20 | 2007-09-25 | Microbix Biosystems Inc. | Improvements in virus production |
| US8877187B2 (en) * | 2005-07-25 | 2014-11-04 | Avianax, Llc | Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases |
| US20070065452A1 (en) * | 2005-07-25 | 2007-03-22 | Avianax | Therapeutic antibodies for treatment and prophylaxis of transmittable viral diseases |
| EP1808697A1 (en) * | 2006-01-13 | 2007-07-18 | Novartis Vaccines and Diagnostics, Inc. | Use of an ion exchange matrix for determining the concentration of virus particles and/or virus antigens |
| WO2007146197A1 (en) * | 2006-06-09 | 2007-12-21 | Xing-Xiang Li | Methods and reagents for virus isolation and detection |
| EP1878791A1 (en) | 2006-07-11 | 2008-01-16 | Bia Separations D.O.O. | Method for influenza virus purification |
| US8481298B2 (en) * | 2006-09-29 | 2013-07-09 | Ge Healthcare Bio-Sciences Ab | Separation matrix for viral purification |
| EP1982727A1 (en) * | 2007-04-17 | 2008-10-22 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Method for purification of viral proteins |
| WO2009006420A2 (en) * | 2007-06-29 | 2009-01-08 | Avianax, Llc | Vaccine production for pathogenic bird viral diseases |
| JP5389342B2 (ja) * | 2007-08-09 | 2014-01-15 | デンカ生研株式会社 | 吸着担体及び吸着担体の製造方法 |
| JP5716297B2 (ja) | 2009-06-25 | 2015-05-13 | Jnc株式会社 | クロマトグラフィー用充填剤、その製造方法、およびそれを用いたウイルス用ワクチンの製造方法 |
| SG184833A1 (en) | 2010-04-14 | 2012-11-29 | Emd Millipore Corp | Methods of producing high titer, high purity virus stocks and methods of use thereof |
| RU2015114330A (ru) | 2012-09-17 | 2016-11-10 | У.Р. Грейс Энд Ко.-Конн. | Хроматографические среды и устройства |
| JP6369467B2 (ja) | 2013-09-02 | 2018-08-08 | Jnc株式会社 | 多孔性セルロース粒子の製造方法および多孔性セルロース粒子 |
| DE102013017014B4 (de) | 2013-10-14 | 2017-03-30 | Sartorius Stedim Biotech Gmbh | Sulfatierte Cellulosehydrat-Membran, Verfahren zur ihrer Herstellung und Verwendung der Membran als Adsorptionsmembran für die Virenaufreinigung |
| CN107847907A (zh) | 2014-05-02 | 2018-03-27 | 格雷斯公司 | 官能化载体材料以及制备和使用官能化载体材料的方法 |
| EP2966093A1 (en) * | 2014-07-07 | 2016-01-13 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Process for the preparation of magnetic sulfated cellulose particles, magnetic sulfated cellulose particles and their use |
| SG10201911134QA (en) | 2015-06-05 | 2020-01-30 | Grace W R & Co | Adsorbent bioprocessing clarification agents and methods of making and using the same |
| US10626376B2 (en) | 2016-11-14 | 2020-04-21 | St. Jude Children's Research Hospital | Method for isolating and purifying adeno-associated virus particles using salt |
| CN106622159B (zh) * | 2016-12-22 | 2019-06-14 | 苏州楚博生物技术有限公司 | 用于蛋白药物纯化的亲和层析介质 |
Family Cites Families (15)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| NL131092C (en, 2012) * | ||||
| US3105012A (en) * | 1961-10-19 | 1963-09-24 | Parke Davis & Co | Antigen products and means for producing the same |
| BE662899A (en, 2012) * | 1964-04-22 | |||
| US3547779A (en) * | 1968-12-18 | 1970-12-15 | Merck & Co Inc | Process for producing purified concentrated influenza virus |
| SE356735B (en, 2012) * | 1970-12-02 | 1973-06-04 | Svenska Cellulosa Ab | |
| US3842062A (en) * | 1972-09-27 | 1974-10-15 | Du Pont | Water-soluble complexes of protein and anionic polyelectrolytes such as sodium carboxymethyl cellulose |
| US3920625A (en) * | 1973-06-19 | 1975-11-18 | Kabi Ab | Isolation of coagulation factors from biological material using cross linked sulfated, sulfonated carbohydrates |
| US4160019A (en) * | 1973-06-25 | 1979-07-03 | Bjorklund Knut B | Detection of cancer associated polypeptide antigen and preparation of antibodies thereto |
| IL49752A (en) * | 1975-07-09 | 1979-07-25 | Kabi Ab | Compositions having affinity for hepatitis virus and method for hepatitis virus removal or concentration |
| SE420977B (sv) * | 1976-03-18 | 1981-11-16 | Kabi Ab | Forfarande for rening och isolering av hepatitvirus for vaccinframstellning |
| US4181713A (en) * | 1978-10-30 | 1980-01-01 | Merck & Co., Inc. | Isolation of HBs Ag |
| DE3014189A1 (de) * | 1980-04-14 | 1981-10-15 | Europäisches Laboratorium für Molekularbiologie (EMBL), 6900 Heidelberg | Verfahren zur herstellung eines immunogenen membranproteinaggregats von influenza-, parainfluenza- und rhabdo-viren |
| JPS57136528A (en) * | 1981-02-09 | 1982-08-23 | Hayashibara Biochem Lab Inc | Preparation of viral vaccine |
| US4434093A (en) * | 1982-07-26 | 1984-02-28 | Ortho Diagnostic Systems Inc. | Methods for preparation of HBs Ag free gamma globulins |
| US4515714A (en) * | 1983-03-09 | 1985-05-07 | Juridicial Foundation, The Chemo-Semo-Sero-Therapeutic Research Institute | Method for purification of hepatitis B virus surface antigen |
-
1984
- 1984-08-09 JP JP59167324A patent/JPS6147186A/ja active Granted
-
1985
- 1985-08-08 CA CA000488281A patent/CA1251399A/en not_active Expired
- 1985-08-08 AT AT85110012T patent/ATE54468T1/de not_active IP Right Cessation
- 1985-08-08 DE DE8585110012T patent/DE3578613D1/de not_active Expired - Lifetime
- 1985-08-08 EP EP85110012A patent/EP0171086B1/en not_active Expired - Lifetime
- 1985-08-09 US US06/764,128 patent/US4724210A/en not_active Expired - Lifetime
- 1985-08-09 KR KR1019850005760A patent/KR920009733B1/ko not_active Expired
Cited By (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1662003A2 (en) | 2000-11-08 | 2006-05-31 | DNAVEC Research, Inc. | Paramyxovirus vector for gene transfer to the cardiovascular system |
| WO2005042737A1 (ja) | 2003-11-04 | 2005-05-12 | Dnavec Research Inc. | 遺伝子導入された樹状細胞の製造方法 |
| WO2006134917A1 (ja) | 2005-06-14 | 2006-12-21 | Dnavec Corporation | 抗体の作製方法 |
| WO2007083644A1 (ja) | 2006-01-17 | 2007-07-26 | Dnavec Corporation | 新規タンパク質発現系 |
| WO2008007581A1 (fr) | 2006-07-13 | 2008-01-17 | Dnavec Corporation | Vecteur de virus paramyxoviridae non répliquant |
| WO2008136438A1 (ja) | 2007-04-27 | 2008-11-13 | Kyushu University, National University Corporation | 遺伝子治療用ウイルスベクター |
Also Published As
| Publication number | Publication date |
|---|---|
| EP0171086A2 (en) | 1986-02-12 |
| DE3578613D1 (de) | 1990-08-16 |
| EP0171086B1 (en) | 1990-07-11 |
| CA1251399A (en) | 1989-03-21 |
| KR920009733B1 (ko) | 1992-10-22 |
| KR870001835A (ko) | 1987-03-28 |
| US4724210A (en) | 1988-02-09 |
| JPS6147186A (ja) | 1986-03-07 |
| EP0171086A3 (en) | 1988-01-13 |
| ATE54468T1 (de) | 1990-07-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JPS6230752B2 (en, 2012) | ||
| Klenk et al. | Glycosphingolipids of plasma membranes of cultured cells and an enveloped virus (SV5) grown in these cells | |
| US4725547A (en) | Method for purfication of rabic virus | |
| CA1216790A (en) | Method for purification of hepatitis b virus surface antigen | |
| US4725546A (en) | Method for purification of Japanese encephalitis virus | |
| JPH0463863B2 (en, 2012) | ||
| KR920009730B1 (ko) | 백일해 성분 백신 및 백일해 항원, 디프테리아 톡소이드 및 파상풍 톡소이드의 혼합백신의 제조방법 | |
| EP0003916A2 (en) | Purification of pertussis Haemagglutinins | |
| McCain et al. | Physicochemical properties of RNA of salmonid hematopoietic necrosis virus (Oregon strain) | |
| JPH0423751B2 (en, 2012) | ||
| JPS6154451A (ja) | 群特異性を有するアフイニテイクロマトグラフイ用ゲルおよびその製法 | |
| EP0170162B1 (en) | Method for the purification of leukocytosis-promoting factor haemagglutinin | |
| JPS632936B2 (en, 2012) | ||
| JPH0235726B2 (en, 2012) | ||
| JP2627186B2 (ja) | レトロウイルスの精製方法 | |
| CA1073355A (en) | Influenza vaccine containing purified neuraminidase antigen and method of using the same | |
| Borecký et al. | Surface Properties of the Egg and Mouse Lines of A1 Influenza Virus | |
| JPS641446B2 (en, 2012) | ||
| JPH0585527B2 (en, 2012) | ||
| JPS60218326A (ja) | 線維状赤血球凝集素の精製方法 | |
| JPS61207334A (ja) | 腫瘍細胞障害性物質 | |
| JPS641448B2 (en, 2012) |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| LAPS | Cancellation because of no payment of annual fees |